학술논문
49O - IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
Document Type
Abstract
Author
Source
In Annals of Oncology December 2018 29 Supplement 10:x17-x17
Subject
Language
ISSN
0923-7534